• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeu ADR (NQ: SMMT )

    9.750 +0.440 (+4.73%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Summit Therapeu ADR

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
    10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
    Via Benzinga
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics Inc.
    Via Business Wire
    7 Top Stocks Under $10: June 2024 Edition
    While blue-chip stocks are great, it's also a good idea to invest in top stocks under $10 to help improve your portfolio's diversification. 
    Via InvestorPlace
    3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
    These high-flying stocks could have more room to run if analysts are right. 
    Via The Motley Fool
    Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
    Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
    Via Talk Markets
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Five Below Posts Weak Q1 Results, Joins Sprinklr, Dorian LPG And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Why Summit Therapeutics Stock Is Trading 8% Higher Monday
    Based on data from a Phase III HARMONi-A clinical trial, sponsored by Akeso, that showed promising results for treating certain cancers, China granted Summit the marketing authorization. 
    Via Benzinga
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
    From Summit Therapeutics Inc.
    Via Business Wire
    Day Trading During A Slow Holiday Week
    We made it to the end of a holiday-shortened week. It was a slow week of day trading, but I’m happy with how it finished. Let’s break it down in today’s recap. 
    Via Talk Markets
    Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
    Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in... 
    Via Talk Markets
    Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
    From Summit Therapeutics Inc.
    Via Business Wire
    Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
    From Summit Therapeutics Inc.
    Via Business Wire
    Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
    Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company announced Phase 3 HARMONi-2 trial results, where ivonescimab significantly... 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers on Friday morning! 
    Via InvestorPlace
    Marvell Technology Posts Weak Q1 Results, Joins MongoDB, Dell Technologies And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics Inc.
    Via Business Wire
    Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
    From Summit Therapeutics Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why Summit Therapeutics Stock Is Sinking Today
    Investors continue to react negatively to recent late-stage results for Summit's experimental cancer therapy. 
    Via The Motley Fool
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.